Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.
about
Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Phase 1/2 trial of temsirolimu ...... nt Group Study/Alliance N0572.
@en
Phase 1/2 trial of temsirolimu ...... nt Group Study/Alliance N0572.
@nl
type
label
Phase 1/2 trial of temsirolimu ...... nt Group Study/Alliance N0572.
@en
Phase 1/2 trial of temsirolimu ...... nt Group Study/Alliance N0572.
@nl
altLabel
Phase 1/2 trial of temsirolimu ...... ent Group Study/Alliance N0572
@en
prefLabel
Phase 1/2 trial of temsirolimu ...... nt Group Study/Alliance N0572.
@en
Phase 1/2 trial of temsirolimu ...... nt Group Study/Alliance N0572.
@nl
P2093
P2860
P356
P1433
P1476
Phase 1/2 trial of temsirolimu ...... nt Group Study/Alliance N0572.
@en
P2093
Caterina Giannini
David Schiff
Erin Twohy
Jan C Buckner
Janet Dancey
Jann N Sarkaria
John F Schwerkoske
John Wright
Kurt A Jaeckle
Patrick J Flynn
P2860
P304
P356
10.1002/CNCR.31219
P407
P577
2018-01-03T00:00:00Z